For a long time, doctors could only treat the symptoms of Huntington's disease (HD). Now, researchers are looking at ways to target the root cause of the disease.
This involves changing how the body handles the gene that causes HD. Several promising approaches are being explored, each with its own way of trying to fix the problem at a genetic level.
Quick Summary
Gene therapy for Huntington's disease aims to reduce the amount of the harmful huntingtin protein produced by the body, rather than just managing symptoms.
Antisense oligonucleotides (ASOs) are short DNA pieces that can block the genetic instructions for making the huntingtin protein.
Some ASOs try to silence both the normal and the faulty huntingtin gene, while others are designed to target only the faulty one.
RNA interference (RNAi) uses small pieces of RNA to interfere with the genetic message, essentially telling the cell to ignore the instructions for making the huntingtin protein.
CRISPR-Cas9 is a gene-editing tool that could potentially correct the genetic error that causes Huntington's disease, though it's still in early research stages.
Getting these therapies to the brain effectively and safely is a major hurdle researchers are working to overcome.
What Is the Primary Goal of Huntington’s Disease Gene Therapy?
How Does Huntington’s Disease Gene Therapy Move Beyond Traditional Symptom Management?
For a long time, treatments for Huntington's disease have focused on managing the symptoms that arise as the brain condition progresses. While these approaches can offer some relief, they don't address the underlying cause of the illness.
Huntington's disease is a genetic disorder, meaning it's caused by a specific change in a person's DNA. This change leads to the production of a faulty protein, called mutant huntingtin (mHTT), which is toxic to nerve cells, particularly in the brain.
The ultimate aim of gene therapy for HD is to go beyond just easing symptoms and instead target the genetic root of the problem. This involves finding ways to stop the production of this harmful mHTT protein or even correct the genetic error itself.
What Does It Mean to Lower the Huntingtin Protein in Huntington’s Disease Research?
When we talk about 'lowering the huntingtin protein' in the context of HD gene therapy, we're referring to reducing the amount of the mutant huntingtin protein that the body produces.
The huntingtin gene normally provides instructions for making a protein that's important for brain function. However, in Huntington's disease, a specific part of this gene is altered, leading to an expanded repeat of certain DNA building blocks (CAG repeats). This alteration causes the gene to produce a version of the huntingtin protein that is toxic.
The core idea behind many gene therapies is to interfere with the process that creates this toxic protein. This can be done at different stages, but the end goal is to decrease the levels of the mHTT protein in the brain.
It's important to note that most strategies aim to lower the mutant form, while ideally leaving the normal huntingtin protein untouched, as the normal protein plays a vital role in brain health. However, achieving this precise distinction can be a significant challenge.
How Do Antisense Oligonucleotides Work as a Huntington’s Disease Treatment?
Antisense oligonucleotides, or ASOs, represent a significant approach in the quest to manage Huntington's disease at its genetic root.
Think of them as tiny, custom-made pieces of genetic material, specifically designed to interact with the instructions that lead to the production of the huntingtin protein.
Huntington's disease is caused by a faulty gene that produces an abnormal version of the huntingtin protein, often referred to as mutant huntingtin (mHTT). This mHTT protein is toxic to nerve cells, particularly in the brain, and its accumulation leads to the progressive symptoms of the disease.
ASOs work by targeting the messenger RNA (mRNA) that carries the genetic code from the DNA to the cell's protein-making machinery. By binding to this mRNA, ASOs can interfere with the production of the mHTT protein.
How Do Antisense Oligonucleotides Intercept Mutant Huntingtin Protein Instructions?
ASOs are short, synthetic strands of DNA or RNA that are designed to be complementary to a specific sequence of RNA.
In the context of Huntington's, ASOs are engineered to find and bind to the mRNA produced by the huntingtin gene. Once an ASO binds to its target mRNA, it can trigger a few different outcomes.
One common mechanism involves recruiting an enzyme within the cell called RNase H. This enzyme recognizes the ASO-mRNA complex and cleaves, or cuts, the mRNA. This degradation of the mRNA effectively prevents it from being translated into a protein.
The goal is to reduce the amount of mHTT protein produced by the cell. Because ASOs can be designed to bind to specific RNA sequences, they offer a way to precisely target the genetic message.
What Is the Difference Between Allele-Specific and Non-Selective Approaches for Huntington’s?
A key consideration in ASO therapy for Huntington's is whether the ASO should target only the mutant huntingtin (mHTT) gene or both the mutant and the normal (wild-type) huntingtin genes.
Non-selective ASOs: These are designed to reduce the production of huntingtin protein generally. They bind to the mRNA from both the mutant and the normal gene. While this can lower the overall levels of mHTT, it also reduces the levels of the normal huntingtin protein, which is important for brain function. Early clinical trials have explored this type of ASO.
Allele-specific ASOs: These are more sophisticated. They are designed to recognize and bind only to the mRNA produced by the mutant huntingtin gene. This is often achieved by targeting specific genetic variations, or single nucleotide polymorphisms (SNPs), that are present on the mutant gene but not the normal one. The advantage here is that it aims to lower the toxic mHTT protein while leaving the beneficial wild-type huntingtin protein largely unaffected. Research is actively pursuing this more precise approach.
What Are the Main Challenges in Delivering Antisense Oligonucleotides to the Brain?
One of the biggest hurdles for ASO therapy, and indeed for many gene therapies targeting neurological disorders, is getting the treatment to where it needs to go. The brain is protected by the blood-brain barrier, a highly selective membrane that prevents many substances from entering.
For ASOs to be effective in treating Huntington's, they need to reach the nerve cells in the brain and spinal cord. Current strategies for delivery include:
Intrathecal injection: This involves injecting the ASO directly into the cerebrospinal fluid, usually in the lower back. This bypasses the blood-brain barrier to some extent and allows the ASO to distribute within the central nervous system.
Intracerebroventricular injection: This is a more direct method, involving injection into the fluid-filled ventricles within the brain itself.
Developing methods for efficient and widespread distribution of ASOs throughout the brain, while minimizing side effects, remains an active area of research and development.
How Is RNA Interference Used to Target the Mutant Huntingtin Gene?
What Are Small Interfering RNAs and How Do They Help Treat Huntington’s?
RNA interference, or RNAi, is a natural process cells use to control which genes are active. Think of it like a cellular dimmer switch for gene expression.
At the heart of this system are small interfering RNAs, or siRNAs. These are short, double-stranded RNA molecules that can be programmed to find and bind to specific messenger RNA (mRNA) molecules.
Once bound, they signal to the cell's machinery to break down that mRNA, effectively silencing the gene it came from before it can be used to build a protein.
How Does RNA Interference Therapy Differ From Antisense Oligonucleotide Therapy?
While both RNA interference and antisense oligonucleotide therapies aim to reduce the production of the harmful Huntingtin protein, they operate through distinct mechanisms and often require different delivery methods.
The development of allele-specific strategies is a major focus for both ASO and RNAi approaches to ensure only the mutant Huntingtin gene is targeted. This precision is vital for minimizing potential side effects and maximizing therapeutic benefit.
How Can Gene Editing Correct the Genetic Blueprint for Huntington’s Disease?
How Is CRISPR-Cas9 Gene Editing Used in Huntington’s Disease Research?
Gene editing technologies, particularly CRISPR-Cas9, offer a different approach to tackling Huntington's disease. Instead of just silencing the message or the messenger, gene editing aims to directly alter the underlying genetic code.
Think of it like fixing a typo in a book rather than just crossing out the wrong word. The goal here is to precisely target the expanded CAG repeat in the huntingtin gene, which is the root cause of the disease.
CRISPR-Cas9 works like a molecular scissor. It uses a guide RNA molecule to find a specific spot in the DNA, and then the Cas9 enzyme cuts the DNA at that location. For Huntington's, researchers and neuroscientists are exploring ways to use this system to:
Remove or shorten the problematic expanded CAG repeat.
Disable the mutant huntingtin gene entirely.
Correct the mutation to a non-pathological length.
The potential here is to make a permanent correction to the genetic defect. This is a significant departure from therapies that require ongoing administration.
What Are the Potential Benefits and Risks of Permanent Genetic Changes for Huntington's?
While the idea of a one-time genetic fix is incredibly appealing, gene editing also comes with its own set of challenges and considerations. The precision of CRISPR-Cas9 is high, but it's not perfect.
There's always a concern about off-target edits, where the system might make unintended cuts in other parts of the DNA. These unintended changes could potentially lead to other health problems, including cancer.
Another hurdle is getting the CRISPR-Cas9 system safely and effectively into the right cells in the brain. Like other gene therapies, delivery is a major area of research. Scientists are investigating various methods, including using modified viruses (viral vectors) to carry the CRISPR components into brain cells.
Furthermore, the permanence of gene editing raises ethical questions. If a change is made to the DNA, it could potentially be passed down to future generations.
This makes the safety and accuracy of the technology absolutely paramount before it can be widely considered for human use. Neuroscientific research is ongoing to improve the specificity of CRISPR systems and to develop methods for controlling their activity once inside the cell.
What Are the Other Emerging Gene Therapy Strategies for Huntington’s Disease?
How Can Zinc Finger Proteins Help Regulate the Huntington’s Disease Gene?
Beyond the main approaches like ASOs and RNAi, scientists are also looking into other ways to control the huntingtin gene. One such method involves using zinc finger proteins (ZFPs).
These are proteins that can be engineered to bind to specific DNA sequences. The idea is to create ZFPs that can specifically target the mutated huntingtin gene. By binding to this gene, ZFPs could potentially block its activity or even trigger its degradation.
Research in this area has shown that specially designed ZFPs can significantly reduce the production of the mutant huntingtin protein while having a smaller effect on the normal version of the protein. This allele-specific targeting is a key goal for many gene therapy strategies.
What Is the Role of Viral Vectors in Delivering Huntington’s Disease Gene Therapy?
Viral vectors are modified viruses, stripped of their disease-causing abilities, that are used as delivery vehicles. They are engineered to carry the therapeutic genetic material (like the instructions for making an ASO or RNAi molecule) into target cells.
Adeno-associated viruses (AAVs) are a common choice because they are generally safe and can infect a wide range of cells. Researchers are exploring different types of AAVs to see which ones are best at reaching specific brain regions affected by Huntington's disease.
The effectiveness of a gene therapy can depend heavily on how well these viral vectors can deliver their cargo to the intended cells without causing unwanted side effects.
Looking Ahead
The journey to effective gene therapies for Huntington's disease is still ongoing. While ASOs, RNAi, and CRISPR technologies show real promise, they are in different stages of development.
Some have faced setbacks in clinical trials, highlighting the challenges of targeting the disease precisely and safely in humans. Researchers are working hard to refine these methods, aiming for treatments that can specifically silence the faulty huntingtin gene without harming healthy ones.
It's a complex puzzle, but the progress made so far offers hope for future treatments that could potentially alter the course of HD.
References
Rook, M. E., & Southwell, A. L. (2022). Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic: ME Rook et al. BioDrugs, 36(2), 105-119. https://doi.org/10.1007/s40259-022-00519-9
Aslesh, T., & Yokota, T. (2020). Development of antisense oligonucleotide gapmers for the treatment of Huntington’s disease. Gapmers: Methods and Protocols, 57-67. https://doi.org/10.1007/978-1-0716-0771-8_4
Byrnes, A. E., Dominguez, S. L., Yen, C. W., Laufer, B. I., Foreman, O., Reichelt, M., ... & Hoogenraad, C. C. (2023). Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection. Molecular Therapy Nucleic Acids, 32, 773-793. https://doi.org/10.1016/j.omtn.2023.05.005
Belgrad, J., Summers, A., Landles, C., Greene, J. R., Hildebrand, S., Knox, E., Sapp, E., Yamada, N., Furgal, R., Miller, R., Osborne, G. F., Chase, K., Luu, E., Freedman, J., Bramato, B., McHugh, N., Benoit, V., O'Reilly, D., Greer, P., Bates, G. P., … Khvorova, A. (2025). Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington's disease pathogenesis in mice. bioRxiv : the preprint server for biology, 2025.06.24.661398. https://doi.org/10.1101/2025.06.24.661398
Gangwani, M. R., Soto, J. S., Jami-Alahmadi, Y., Tiwari, S., Kawaguchi, R., Wohlschlegel, J. A., & Khakh, B. S. (2023). Neuronal and astrocytic contributions to Huntington’s disease dissected with zinc finger protein transcriptional repressors. Cell reports, 42(1). https://doi.org/10.1016/j.celrep.2022.111953
Frequently Asked Questions
What is the main goal of gene therapy for Huntington's Disease?
The main goal is to fix the problem at its source by changing the faulty gene that causes Huntington's Disease, instead of just treating the symptoms. This involves trying to reduce the harmful protein that the bad gene makes.
What does 'lowering the Huntingtin protein' mean in gene therapy?
It means reducing the amount of the specific protein, called Huntingtin (HTT), that is made from the mutated gene. The mutated version, called mutant Huntingtin (mHTT), is toxic and causes the problems seen in Huntington's Disease. Lowering mHTT aims to stop or slow down the damage it causes to the brain.
How do Antisense Oligonucleotides (ASOs) work?
ASOs are like tiny, custom-made pieces of genetic material. They are designed to find and attach to the messenger RNA (mRNA) that carries instructions from the faulty gene. Once attached, they can block the instructions or signal the cell to break down the mRNA, preventing the harmful protein from being made.
What is the difference between allele-specific and non-selective ASOs?
Non-selective ASOs try to lower all Huntingtin protein, both the normal and the mutated versions. Allele-specific ASOs are more precise; they aim to only lower the Huntingtin protein made from the mutated gene, leaving the normal Huntingtin protein untouched. This is preferred because normal Huntingtin is important for brain health.
Why is it difficult to get ASOs into the brain?
The brain is protected by a barrier called the blood-brain barrier, which is like a security system. It's hard for many substances, including medicines like ASOs, to get through this barrier. Scientists are working on ways to deliver ASOs effectively, such as injecting them directly into the fluid around the brain or spinal cord.
What is RNA Interference (RNAi)?
RNAi is a natural process cells use to control which genes are turned on or off. Scientists can use small pieces of RNA, called small interfering RNAs (siRNAs) or microRNAs (miRNAs), to hijack this process. These tiny RNAs can target the messenger RNA from the faulty gene and cause it to be destroyed, similar to how ASOs work.
What is CRISPR-Cas9 gene editing?
CRISPR-Cas9 is a powerful tool that acts like molecular scissors. It can be programmed to find a specific spot in the DNA and make a precise cut. For Huntington's, the hope is to use CRISPR to either disable the faulty gene entirely or even correct the mistake in the DNA sequence.
What are Zinc Finger Proteins used for in gene therapy?
Zinc finger proteins are another type of tool scientists can engineer. They can be designed to attach to specific DNA sequences and block the gene from being read or turned on. This is another way to 'silence' the faulty gene that causes Huntington's Disease.
What role do viral vectors play in gene therapy delivery?
Since getting gene therapy medicines into the right cells can be tricky, scientists often use viruses that have been modified to be harmless. These 'viral vectors' act like delivery trucks, carrying the therapeutic genetic material (like ASOs or RNAi components) into the cells that need treatment.
Emotiv is a neurotechnology leader helping advance neuroscience research through accessible EEG and brain data tools.
Christian Burgos
